| 1.72 -0.02 (-1.15%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.08 |
1-year : | 2.29 |
| Resists | First : | 1.78 |
Second : | 1.96 |
| Pivot price | 1.68  |
|||
| Supports | First : | 1.5 |
Second : | 1.25 |
| MAs | MA(5) : | 1.74 |
MA(20) : | 1.67 |
| MA(100) : | 3.09 |
MA(250) : | 4.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 42.5 |
D(3) : | 50.7 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 6.17 | Low : | 1.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALDX ] has closed below upper band by 39.8%. Bollinger Bands are 73.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.83 - 1.84 | 1.84 - 1.85 |
| Low: | 1.66 - 1.67 | 1.67 - 1.68 |
| Close: | 1.7 - 1.72 | 1.72 - 1.73 |
Aldeyra Therapeutics, Inc. is a biotechnology company focused on the discovery and commercialization of therapeutic agents for ocular and systemic immune-mediated disorders. The firm's primary investigational compound is reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for addressing dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing ADX-629, an innovative, first-in-class RASP modulator designed for oral administration, which is undergoing Phase II studies for conditions such as psoriasis, asthma, and COVID-19. Another pipeline asset, ADX-2191, a dihydrofolate reductase inhibitor, is in Phase 3 for the prevention of proliferative vitreoretinopathy and in Phase II trials for treating retinitis pigmentosa and primary vitreoretinal lymphoma. The company also holds a license agreement with Madrigal Pharmaceuticals, Inc. for the development of ADX-1612, a compound that inhibits the protein chaperome to tackle inflammatory diseases. Originally incorporated in 2004 as Aldexa Therapeutics, Inc., the company officially adopted the name Aldeyra Therapeutics, Inc. in March 2014 and is headquartered in Lexington, Massachusetts.
Tue, 09 Jun 2026
Aldeyra appoints Darlene Deptula-Hicks to board of directors - Investing.com India
Tue, 09 Jun 2026
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors - Stock Titan
Fri, 05 Jun 2026
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Sign - GuruFocus
Fri, 05 Jun 2026
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Fri, 05 Jun 2026
ALDX News | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
Thu, 04 Jun 2026
ALDX: Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 62.7 (%) |
| Shares Short | 7,580 (K) |
| Shares Short P.Month | 5,540 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -51.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -3.83 |
| PEG Ratio | 0 |
| Price to Book value | 2.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|